The deal will help Clarivate fill a critical need for drug toxicity data and translational safety intelligence across every stage of drug research and development. The Bioinfogate Off-X portal is a safety intelligence tool designed to help pharmaceutical organizations identify toxicology and safety signals, mitigate safety liabilities, and de-risk early-stage assets. The translational safety and toxicity portals feature over 1.2 million safety alerts corresponding to over 23,000 drugs and biologics and more than 15,000 targets of pharmacological interest, according to the firms.

The Bioinfogate acquisition will strengthen Clarivate's ability to support customers across the entire drug development lifecycle, the company said. The terms of the deal were not disclosed.